Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Should You Buy?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $37.77, but opened at $40.00. Structure Therapeutics shares last traded at $39.4220, with a volume of 259,048 shares traded.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GPCR. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. HC Wainwright reduced their target price on shares of Structure Therapeutics from $114.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, March 16th. Citizens Jmp reduced their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $109.25.

Structure Therapeutics Stock Performance

The company’s 50-day moving average is $44.03 and its 200 day moving average is $57.13. The company has a market capitalization of $2.84 billion, a PE ratio of -45.64 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP grew its position in Structure Therapeutics by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares during the last quarter. Avoro Capital Advisors LLC grew its position in Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares during the last quarter. Janus Henderson Group PLC grew its position in Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after purchasing an additional 264,833 shares during the last quarter. BVF Inc. IL grew its position in Structure Therapeutics by 8.6% during the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the last quarter. Finally, Morgan Stanley grew its position in Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after purchasing an additional 1,510,093 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.